Iain Shaw is Senior Director of 14C Enabled Drug Development at Quotient Sciences and has over 30 years of experience in the pharmaceutical industry, including over 15 years specifically focussed on 14C enabled drug development.

Iain initially joined Quotient Sciences, as Director of Customer Service in 2008. Today, he is responsible for the portfolio of 14C programs that Quotient offer to address questions around drug metabolism and pharmacokinetics using human ADME, microADME, intravenous microtracer techniques and our Synthesis-to-Clinic integrated programmes.

Prior to joining Quotient Sciences, Iain held early development program management, clinical development, and analytical positions at pharmaceutical companies and contract research organizations (CROs) including Covance (now Lab Corp Drug Development) and PPL Therapeutics.